Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI) - Park, K; Lee, J S; Lee, K H (J Clin Oncol)
33, 2015 (suppl; abstr 8084).